The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

BMC Infectious Diseases

Matthew Pillsbury⁵  Mikk Jürisson¹  Mait Raag³  Kosuke Kawai²  Andres Müürsepp⁴  Anneli Uusküla³ 

[1] East Tallinn Central Hospital, Tallinn, Estonia;Temple University, Philadelphia, PA 19140, USA;Department of Public Health, University of Tartu, Ravila st 19, Tartu 50411, Estonia;Merck Sharp & Dohme OÜ, Tallinn, Estonia;Atlas Data Systems, Westfield, NJ, USA

关键词: Estonia;    Genital warts;    Cervical cancer;    Screening;    Cost effectiveness;    Vaccine;    HPV;   

Others  :  1147269
DOI  :  10.1186/1471-2334-13-304

 received in 2012-12-12, accepted in 2013-06-19,  发布年份 2013

【 摘 要 】

Background

This analysis assessed the epidemiological and economic impact of quadrivalent human papillomavirus (HPV4: 6/11/16/18) vaccination in Estonia.

Methods

A dynamic transmission model was used to assess the epidemiological and economic impact of the routine vaccination of 12-year-old girls with a HPV4 vaccine in preventing cervical cancer, cervical intraepithelial neoplasia (CIN) grades 1, 2 and 3 and genital warts.

Results

The model projected that at year 100, HPV4 vaccination would lead to a reduction of HPV 16/18 related cervical cancer incidence and deaths by over 97% and the incidence of HPV 6/11 related genital warts among Estonian women and men by over 94% and 81%, respectively. The incremental cost-effectiveness ratio of the HPV4 vaccination strategy was € 4,889 per QALY gained over a time horizon of 100 years.

Conclusions

Routine vaccination of 12-year-old girls with HPV4 vaccine appears to be cost-effective in Estonia, in addition to providing both short term and long term health gains.

【 授权许可】

   
2013 Uusküla et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Seto K, Marra F, Raymakers A, Marra CA: The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs 2012, 72(5):715-743.
• [2]Vanagas G, Padaiga Z, Kurtinaitis J, Logminiene Z: Cost-effectiveness of 12-and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. Scand J Public Health 2010, 38(6):639-647.
• [3]Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH: The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010, 13(1):110-118.
• [4]Obradovic M, Mrhar A, Kos M: Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health 2010, 20(4):415-421.
• [5]Kostinov MP, Zverev VV: [Economic effectiveness of vaccination against papilloma virus in the Russian Federation]. Zh Mikrobiol Epidemiol Immunobiol 2012, 2:43-50. [Article in Russian]
• [6]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr webcite
• [7]Eesti haigekassa 2010 (HIF 2010): Haiguste ennetamise projektide 2010. aasta tulemused (The results of the disease prevention pojrects in 2010. 2010. http://www.haigekassa.ee/uploads/userfiles/2010_HE_tulemused.pdf webcite
• [8]Veerus P, Arbyn M, Amati C, Paolo B, EUROCHIP Working Group: Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori 2010, 96(4):524-528.
• [9]State agency of medicines, Estonia: Marketing authorisation of medicinal products. http://193.40.10.165/register/register.php?keel=eng&inim_vet=inim webcite
• [10]Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-6867.
• [11]Estonian health insurance fund: Data on insured by EHIF in 2008. 2008. http://www.haigekassa.ee/uploads/userfiles/V15_4_kv__2008_kindlustatute_statistika_prioriteet_gruppides.xls webcite
• [12]Statistics Estonia: Population of Estonia. http://www.stat.ee webcite
• [13]National institutes of health: Estonian Health Interview Survey 2006 (EHIS 2006). 2006. http://www2.tai.ee/ETeU/met_51.pdf webcite
• [14]Surveillance, Epidemiology, and End Results (SEER) program: Public-use data (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. 2005. http://www.seer.cancer.gov webcite
• [15]Liiv K, Lutsar K, Palm E, Uusküla A, Kiivet RA: Inimese papilloomiviiruse Vastaste vaktsiinide kulutõhusus Eestis. Tartu Ülikooli tervishoiu instituut 2011. (Cost effectiveness of human papillomavirus vaccines in Estonia. Department of public health, University of Tartu, 2011); 2011. http://www.rahvatervis.ut.ee/bitstream/1/4921/1/Lutsar2011.pdf webcite
• [16]Estonian Health Board: National immunization program implementation. 2010. http://www.terviseamet.ee/nakkushaigused/vaktsineerimine/riiklik-immuniseerimiskava-ja-selle-taitmine.html webcite
• [17]Gold MR, Siegel JE, Russell LB, Mce W: Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
• [18]Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organisation; 2003.
• [19]Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22(12):2675-2686.
• [20]Eurostat: GDP and main components - Current prices. 2012. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_gdp_c&lang=en webcite
• [21]World health organization: CHOosing Interventions that are Cost Effective (WHO-CHOICE). 2009. http://www.who.int/choice/book/en/index.html webcite
• [22]Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365(17):1576-1585.
• [23]Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(10):868-878.
• [24]II Study Future Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 19:1915-1927.
• [25]International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention: Cervix Cancer Screening. Lyon: IARC Press; 2005:10.
• [26]van Ballegooijen M, van den Akker-van ME, Patnick J, Lynge E, Arbyn M, Anttila A: Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000, 36(17):2177-2188.
• [27]Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M: Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004, 91(5):935-941.